MedTrace Logo

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

NCT06678074 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-03-27

No results posted yet for this study

Summary

Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment).

Conditions

  • STEMI
  • STEMI (ST Elevation MI)
  • STEMI - ST Elevation Myocardial Infarction (MI)
  • Stent Implantation

Interventions

DRUG

Atibuclimab (IC14), 20 mg/kg intravenously, once

monoclonal antibody against CD14

OTHER

Placebo, 150 mL intravenously, once

sterile normal saline for injection

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • University of Virginia

    collaborator OTHER

  • Implicit Bioscience

    lead INDUSTRY

Principal Investigators

  • Marc Sintek, MD · PI

  • Antonio Abbate, MD, PhD · PI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-06
Primary Completion
2026-06-01
Completion
2026-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06678074 on ClinicalTrials.gov